We are excited to see Palvella Therapeutics continued progress to advance QTORIN?, a potential treatment for microcystic lymphatic malformations, a rare and chronically debilitating genetic disease. ? The #FDA Office of Orphan Products Development awards grants annually to support the development of safe and effective medical products to address unmet medical needs for patients with rare diseases or conditions. Palvella’s Phase 3 QTORIN? clinical trial was 1 of 7 new clinical trials that was awarded a grant in 2024. ? Read more ?
Today, we announced Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million which will support the advancement of our ongoing Phase 3 single-arm baseline-controlled trial in microcystic lymphatic malformations. This underscores our belief in the potential of QTORIN? rapamycin which has also received FDA Breakthrough Therapy, Fast Track, and Orphan Designations for this serious, rare and chronically debilitating genetic disease. Learn more: https://bit.ly/3BrEnnz #lymphaticmalformations #raredisease?
